Work

Phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic urothelial carcinoma (UC) or renal cell carcinoma (RCC).

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.5_suppl.tps42

Authors: Manuel C. Maia, Neeraj Agarwal, Bradley Alexander McGregor, Ulka N. Vaishampayan, Toni K. Choueiri, Marjorie C. Green, Colin Hessel, Christian Scheffold, Gisela Schwab, Thomas Powles, Sumanta K. Pal, XL184-021 study group

Institutions: City Of Hope National Medical Center, Huntsman Cancer Institute, Dana-Farber Cancer Institute, The Barbara Ann Karmanos Cancer Institute, Brigham and Women's Hospital, Harvard University, Dana-Farber Brigham Cancer Center, Genentech, Exelixis (United States), Queen Mary University of London, Barts Cancer Institute

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2792869479

Cites:

Cited by: 4

Related to: 10